A tumour doesn’t form overnight. Researchers at Hoag Family Cancer Institute in California report a molecular signal in the blood that flags the earliest changes behind ovarian cancer, long before anything would show on a scan. They have developed an experimental ovarian cancer blood test to measure it. The work, published in Nature Medicine on 10 November 2026, could change how women with BRCA1 or BRCA2 mutations weigh a decision they now make on inherited risk alone: whether to remove healthy ovaries and fallopian tubes, or wait for evidence that disease has begun. The test is investigational and is not yet available to patients.
What happened?
Director of translational research at Hoag Family Cancer Institute, Dr Rajan Gogna, and Dr Esha Madan, who runs the institute’s Cell Competition in Tumour Microenvironment Laboratory, led this multi-institutional and international effort, which took eight years to complete. It set out to answer one question: can a blood test detect ovarian cancer before it is cancer?
They worked with blood samples already collected from women with known diagnoses, gathered by clinical collaborators in several countries. Hoag has not released the number of women, countries or institutions involved. The aim was deliberately narrow: to find something measurable in blood before a tumour becomes detectable.
How Does the New Ovarian Cancer Blood Test Work?
The majority of high-grade serous ovarian carcinoma, which is the deadliest and most common form of ovarian cancer, actually originates in the fallopian tube. It starts in a small patch of abnormal cells known as STIC (Serous Tubal Intraepithelial Carcinoma), These cells are microscopic and have not yet spread, so neither imaging scans nor commonly used blood tests such as CA125 can pick them up. Mostly, they are discovered coincidentally during a surgery for other purposes.
What the team zeroed in on is an RNA molecule they named Tu-Stroma. RNA carries the instructions cells use to build proteins and regulate themselves, and this particular molecule turns out to be tied to something called cell competition, essentially, early cancer cells muscling out the healthy tissue around them to make room to grow. Women with STIC or early invasive ovarian cancer had higher blood levels of Tu-Stroma, even when the disease itself was far too small to spot any other way. Tu-Stroma travels in extracellular vesicles, the tiny membrane-bound particles cells use to carry material to one another, and the test measures it there. That rise is the signal the test is built to catch.
Ovarian Cancer Blood Test: Key Findings
- In a separate validation group, the new ovarian cancer blood test detected STIC in 92.3% of the women who had it (sensitivity).
- The specificity was 98.2%, which means healthy women would very rarely be wrongly diagnosed as having STIC.
- In a modelled high-risk population, such as BRCA1 or BRCA2 carriers, about 72% of positive results would be correct, and a negative result would be correct close to 100% of the time. These are modelled estimates, not results from a screening trial.
- High levels of Tu-Stroma were not confined to only the late or advanced stages but could also be detected in STIC and early invasive cancers.
- The work ran for eight years and was international and multi-institutional, using clinical samples collected by several research groups. Hoag has not published the number of participants, countries or institutions.
Why does it matter?
Carrying a BRCA1 or BRCA2 mutation raises the lifetime odds of ovarian cancer enough that many women choose to have their tubes and ovaries removed before cancer ever develops. That’s a major decision, and right now it’s made almost entirely on inherited risk: there’s no biological signal telling anyone whether disease has actually begun. Dr Madan says this test could fill exactly that gap, giving women and their doctors something firmer to go on when deciding whether, or when, to operate.
According to Dr Gogna, this research is a strategic shift. Rather than tracking down smaller tumours, the target became identifying a sign: the new ovarian cancer blood test aims to identify biological warning signs before invasive cancer develops. This matters because ovarian cancer is most often diagnosed only after it has already spread. This is one of the reasons why ovarian cancer survival rates have hardly improved and are low. If the findings hold up in prospective studies and the test clears clinical validation and regulatory review, it could support a shift towards detecting the disease earlier and trying to stop it progressing. That remains a possibility rather than an established outcome.
What does it mean for life-science students & careers in India and abroad?
This kind of exceptional study of advanced research provides a clear understanding of what a career in cancer looks like. Studies on RNA markers, biostatistics, genomics, and liquid biopsies demonstrate the effectiveness of diagnostic methods in healthcare. The conclusion that can be drawn by the students of Life Sciences is clear: today, cancer research requires experienced specialists dealing with three important components of research work, that is, biological datasets, benchmark conducting, and clinical trial designs.
Translational oncology increasingly operates through international collaborations. Thus, Indian life sciences graduates aspiring to a future in genetic risk counselling, precision oncology, or molecular diagnostics should consider international collaborations. International exposure through a collaborative diagnostics company, a PhD programme or an overseas fellowship can strengthen a profile in these areas, though the extent to which it counts varies by field, employer and country.
What’s Next for Early Ovarian Cancer Detection?
Now comes the difficult challenge of prospective studies involving patients from both Hoag and the broader communities, some with mutations in BRCA1 or BRCA2 and others without. These studies are still in the planning stage. As Hoag describes them, they would involve collecting blood samples and following participants over time to determine when the Tu-Stroma signal first appears, how reliably it identifies women with precursor disease, and whether it can safely guide clinical decisions. No timeline has been announced. Simultaneously, the researchers are working on ways to prevent STIC from developing into invasive cancer, an effort that, if it succeeds, could reduce the need for preventive surgery. The team’s stated long-term goal is a clinically validated blood test for ovarian cancer surveillance and prevention. Neither that validation nor any regulatory approval has happened yet.
A point to note is that these figures are based on samples with diagnoses, and not on screening in a general population sample, which would be a completely different type of test. Furthermore, the disclosed information doesn’t provide any details on the number of women who participated in the research, nor does it state the number of countries and institutions that participated. Moreover, the high-risk figures, the 72% positive predictive value and the near-100% negative predictive value, are modelled estimates rather than results from a high-risk screening trial.
The New Ovarian Cancer Blood Test – FAQs
-
What is STIC, and why is it so hard to catch early?
STIC, or Serous tubal intraepithelial carcinoma, refers to a patch cluster of abnormal cells found on the fallopian tube lining which may eventually develop into ovarian cancer. This condition is difficult to detect since it cannot be seen through scans, is microscopic and goes unnoticed in a regular blood test such as CA125. In most cases, the diagnosis is made by coincidence during another surgery.
-
What is Tu-Stroma?
It is an RNA molecule associated with a phenomenon known as “cell competition,” in which early cancer cells exclude and weaken surrounding healthy tissues in the body. The amount of this molecule is elevated in the bloodstream of women suffering from either STIC or early-stage ovarian cancer, which is precisely what the new test detects.
-
How accurate is the test?
In the separate validation group, 92.3% of women who had STIC were correctly identified and 98.2% of healthy women were correctly cleared. For women at high genetic risk, modelling puts positive results holding up around 72% of the time, with negative results correct close to 100% of the time. Those high-risk figures are modelled, not measured in a screening trial.
-
Can I get this New Ovarian Cancer Blood Test done right now?
Not yet. This is still a research finding, built on previously collected samples. Before it could reach patients, it would need to undergo the prospective clinical studies that Hoag is planning, followed by clinical validation and regulatory review. No timeline has been announced.
